Document is current

Article History

Received: 13 May 2020

Accepted: 19 June 2020

First Online: 29 June 2020

Ethics approval and consent to participate

: This study is being performed in accordance with the principles of the Declaration of Helsinki and each recruiting centre has ethical approval from their local Ethical review committee (Leeds/Sheffield: study was approved by Yorkshire & The Humber - South Yorkshire Research Ethics Committee, ref.: 18/YH/0077; Exeter: study was approved by South West - Exeter Research Ethics Committee, reference 18/SW/0061; Turku: study approved by Ethical committee of Hospital District of South West Finland, reference: 123 /1801/2017; Bordeaux: Study approved by CPP Est II, ref.: 18/581; Bari: study approved by Independent Ethics Committee of the Policlinic Hospital in Bari, ref.: 5760). Written, informed consent to participate in this study is being obtained from all participants, in line with local guidelines.

: Not applicable.

: This work forms part of the BEAt-DKD consortium that is funded by the IMI 2 Joint Undertaking that receives support from the European Federation of Pharmaceutical Industries and Associations (EFPIA). BEAt-DKD EFPIA partners that have contributed to the iBEAT study development are Astellas, AbbVie and Novo Nordisk. JDRF also contributed to the iBEAT study design. AMDA reports grants from Boehringer Ingelheim Pharma GmbH during the conduct of the study. AZ reports non-financial support and other from Boehringer Ingelheim Pharma GmbH during the conduct of the study. MG reports personal fees from Lilly and other from Sanofi Genzyme, outside of the submitted work. DZ reports other from Fresenius, other from Boehringer Ingelheim, other from Bayer, other from Mitsubishi Tanabe, other from Mundipharma, other from Janssen, other from AbbVie, outside the submitted work. HJLH reports other from Merck, other from Mitsubishi Tanabe, grants and other from Janssen, other from Mundipharma, other from Gilead, grants and other from AstraZeneca, grants and other from Abbvie, other from Retrophin, outside the submitted work. MK reports grants from NIH, non-financial support from University of Michigan, during the conduct of the study; grants from JDRF, grants from Astra-Zeneca, grants from NovoNordisc, grants from Eli Lilly, grants from Gilead, grants from Goldfinch Bio, grants from Merck, grants from Janssen, grants from Boehringer-Ingelheim, outside the submitted work; In addition, MK has a patent Biomarkers for CKD progression (encompassing urinary EGF as biomarker of CKD progression) issued. DA reports other from AbbVie, outside the submitted work. MFG reports non-financial support and other from Boehringer Ingelheim Pharma GmbH, non-financial support and other from JDRF International, non-financial support and other from Eli Lilly, non-financial support and other from AbbVie, non-financial support and other from Sanofi-Aventis, non-financial support and other from Astellas, non-financial support and other from Novo Nordisk A/S, non-financial support and other from Bayer AG, during the conduct of the study; personal fees from Lilly, non-financial support and other from Novo Nordisk, non-financial support and other from Pfizer, non-financial support and other from Follicum, non-financial support and other from Abcentra, non-financial support from Probi, non-financial support from Johnson & Johnson, outside the submitted work. SS reports non-financial support from Siemens, during the conduct of the study.